



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12th February 2025

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001.

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/ Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December 2024 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (“Listing Regulations”) along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information.
2. Declared third interim dividend of Rs. 1.50/- (Rupees One and Paise fifty only) (75 %) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2024-25. The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e., record date is fixed as Tuesday, the 18th February, 2025. The payment of said interim dividend will start from 28th February, 2025.
3. The Board took note of the resignation tendered by Dr. Pavan Ganapati Bhat (DIN: 09691260), Director & Executive Vice President (Technical Operations) of the Company due to new career opportunity outside the Company, with effect from the close of the business hours on 12th February, 2025. Consequently, he shall also cease to be the member of the Risk management Committee of the Company.

A Copy of the Press Release is enclosed.

Meeting commenced at 1:25 p.m. and concluded at 3:40 p.m.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2024

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations	4,748	13,711	7,586	32,085	29,305	39,988
2	Other income	1,763	638	370	2,882	861	1,281
3	Total income (1+2)	6,511	14,349	7,956	34,967	30,166	41,269
	Expenses						
	Cost of materials consumed	727	1,432	922	3,672	3,949	5,225
	Purchases of stock-in-trade	391	537	367	1,253	1,203	1,514
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(290)	(193)	333	(519)	588	427
	Employee benefits expense	1,416	1,515	1,219	4,351	3,825	5,250
	Finance costs	44	41	46	137	130	192
	Depreciation and amortisation expense	470	458	442	1,369	1,313	1,868
	Other expenses	2,116	2,377	2,064	6,849	7,199	10,058
	Total expenses	4,874	6,167	5,393	17,112	18,207	24,534
5	Profit before tax for the period/ year (3-4)	1,637	8,182	2,563	17,855	11,959	16,735
6	Tax expense						
	(i) Current tax	335	1,541	522	3,312	2,262	3,165
	(ii) Deferred tax	(22)	(124)	(86)	(231)	(323)	(313)
	Total tax expense	313	1,417	436	3,081	1,939	2,852
7	Profit for the period/ year (5-6)	1,324	6,765	2,127	14,774	10,020	13,883
8	Other comprehensive income/ (loss) (net of tax)						
	(i). Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit liability/(asset)	-	-	-	-	-	(20)
	Tax on remeasurement of defined benefit liability/(asset)	-	-	-	-	-	7
	Fair value changes of Equity investments through OCI	180	50	28	256	104	97
	Tax impact in Fair value changes on Equity investments through OCI	(26)	(7)	(3)	(37)	(10)	(8)
		154	43	25	219	94	76
	(ii). Items that will be reclassified to profit or loss:						
	Exchange differences on translating financial statements of foreign operations	(260)	149	154	(277)	180	73
		(260)	149	154	(277)	180	73
	Other comprehensive income/ (loss) for the period/ year, net of tax	(106)	192	179	(58)	274	149
9	Total comprehensive income for the period/ year (7+8)	1,218	6,957	2,306	14,716	10,294	14,032
10	Profit for the period/year attributable to:						
	Owners of the Company	1,330	6,773	2,127	14,788	10,020	13,883
	Non-controlling interests	(6)	(8)	-	(14)	-	-
11	Other comprehensive income for the period/ year attributable to:						
	Owners of the Company	(106)	192	179	(58)	274	149
	Non-controlling interests	-	-	-	-	-	-
12	Total comprehensive income for the period/ year attributable to:						
	Owners of the Company	1,224	6,965	2,306	14,730	10,294	14,032
	Non-controlling interests	(6)	(8)	-	(14)	-	-
13	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358	358	358
14	Other equity						58,173
15	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)						
	Basic (in ₹)	7.43	37.81	11.88	82.56	55.78	77.34
	Diluted (in ₹)	7.43	37.81	11.88	82.56	55.78	77.34

See accompanying notes to the unaudited consolidated financial results.

Continued..



NATCO Pharma Limited

Segment reporting:

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment revenue						
	a. Pharmaceuticals	4,597	13,562	7,445	31,629	28,159	38,905
	b. Agro chemicals	151	149	141	456	1,146	1,083
		4,748	13,711	7,586	32,085	29,305	39,988
	Add: Unallocated	-	-	-	-	-	-
	Total revenue from operations	4,748	13,711	7,586	32,085	29,305	39,988
2	Segment results						
	a. Pharmaceuticals	1,894	8,461	2,759	18,641	12,155	17,523
	b. Agro chemicals	(213)	(238)	(150)	(649)	(66)	(596)
	Total segment result	1,681	8,223	2,609	17,992	12,089	16,927
	Less:						
	a. Finance costs	(44)	(41)	(46)	(137)	(130)	(192)
	b. Net unallocated (income)/expenditure	-	-	-	-	-	-
	Total profit before tax	1,637	8,182	2,563	17,855	11,959	16,735
3	Segment assets						
	a. Pharmaceuticals	44,021	51,295	53,730	44,021	53,730	45,650
	b. Agro chemicals	3,571	4,057	4,140	3,571	4,140	4,238
	Total segment assets	47,592	55,352	57,870	47,592	57,870	49,888
	Add:						
	a. Unallocated	33,561	27,095	6,094	33,561	6,094	19,175
	Total assets	81,153	82,447	63,964	81,153	63,964	69,063
4	Segment liabilities						
	a. Pharmaceuticals	5,682	7,072	7,007	5,682	7,007	5,807
	b. Agro chemicals	328	463	73	328	73	588
	Total segment liabilities	6,010	7,535	7,080	6,010	7,080	6,395
	Add:						
	a. Unallocated	2,629	3,344	1,867	2,629	1,867	4,137
	Total liabilities	8,639	10,879	8,947	8,639	8,947	10,532

Continued..



NATCO Pharma Limited

Notes to the unaudited consolidated financial results:

- 1) The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter and nine months ended 31-12-2024 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-02-2025.
- 3) The unaudited consolidated financial results of the Group for the quarter and nine months ended 31-12-2024, have been reviewed by the statutory auditors and they have issued an unmodified reviewed report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The unaudited consolidated financial results for the quarter and nine months ended 31-12-2024 includes financial results of the following subsidiaries/step-down subsidiaries:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC (Formerly known as Dash Pharmaceuticals LLC, USA - name changed w.e.f. 12-04-2023)	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited (w.e.f. 04-09-2023)	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma (w.e.f. 28-08-2023)	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S. (w.e.f. 15-08-2023)	Colombia	Wholly owned Subsidiary

- 5) The unaudited standalone financial results, for the quarter and nine months ended 31-12-2024 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of unaudited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

(₹ in millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income	5,756	13,440	6,548	31,963	26,729	36,736
Profit before tax	1,503	7,969	2,236	17,052	11,228	15,553
Net profit for the period/ year	1,249	6,611	1,920	14,223	9,575	13,066
Total comprehensive income for the period/ year	1,403	6,654	1,945	14,442	9,669	13,142

- 6) The Board of Directors at their meeting held on 12-02-2025 have approved an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 31-12-2024. An interim dividend of ₹ 3 /- per equity share of ₹ 2 each for the quarter ended 30-06-2024 and an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 30-09-2024 was approved by Board of Directors at their meetings held on 12-08-2024 and 12-11-2024 respectively.

**By order of the Board
For NATCO Pharma Limited**

V C Nannapaneni
Chairman & Managing Director

(DIN: 00183315)

Place: Hyderabad

Date: 12 February 2025

Limited Review Report on unaudited consolidated financial results of NATCO Pharma Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities :

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma Inc., United States of America ('USA')	Subsidiary
NATCO Pharma USA LLC, USA (Formerly known as Dash Pharmaceuticals LLC, USA - name changed w.e.f. 12 April 2023) (Subsidiary of NATCO Pharma Inc.)	Step-down Subsidiary
Time Cap Overseas Limited, Mauritius ('TCOL')	Subsidiary

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400069

Limited Review Report (Continued)

NATCO Pharma Limited

NatcoFarma do Brasil Ltda., Brazil (Subsidiary of TCOL)	Step-down Subsidiary
NATCO Pharma (Canada) Inc., Canada	Subsidiary
NATCO Pharma Asia Pte. Ltd., Singapore	Subsidiary
NATCO Pharma Australia PTY Ltd., Australia	Subsidiary
NATCO Lifesciences Philippines Inc., Philippines	Subsidiary
NATCO Pharma UK Limited, United Kingdom	Subsidiary
PT. NATCO Lotus Farma, Indonesia	Subsidiary
NATCO Pharma Colombia S.A.S.	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of eleven subsidiaries/ step down subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of INR 1,008 million and INR 3,799 million, total net profit after tax (before consolidation adjustments) of INR 65 million and INR 530 million and total comprehensive income (before consolidation adjustments) of INR 65 million and INR 530 million, for the quarter ended 31 December 2024 and for the period from 01 April 2024 to 31 December 2024 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries/ step down subsidiaries are located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries/ step down subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries/ step down subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.

B S R and Co

Limited Review Report (Continued)

NATCO Pharma Limited

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W



Amit Kumar Bajaj

Partner

Membership No.: 218685

UDIN:25218685BMMKCP5483

Hyderabad

12 February 2025



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2024

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from operations	4,076	12,926	6,253	29,371	26,041	35,689
2	Other income	1,680	514	295	2,592	688	1,047
3	Total income (1+2)	5,756	13,440	6,548	31,963	26,729	36,736
	Expenses						
	Cost of materials consumed	727	1,432	922	3,672	3,949	5,225
	Purchases of stock-in-trade	148	133	111	358	268	348
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(172)	(7)	74	(313)	469	172
	Employee benefits expense	1,236	1,328	1,039	3,766	3,299	4,549
	Finance costs	34	30	38	108	100	145
	Depreciation and amortisation expense	437	422	404	1,263	1,203	1,719
	Other expenses	1,843	2,133	1,724	6,057	6,213	9,025
	Total expenses	4,253	5,471	4,312	14,911	15,501	21,183
5	Profit before tax for the period/ year (3-4)	1,503	7,969	2,236	17,052	11,228	15,553
6	Tax expense						
	(i) Current tax	279	1,478	421	3,081	2,012	2,848
	(ii) Deferred tax	(25)	(120)	(105)	(252)	(359)	(361)
	Total tax expense	254	1,358	316	2,829	1,653	2,487
7	Profit for the period/ year (5-6)	1,249	6,611	1,920	14,223	9,575	13,066
8	Other comprehensive income/ (loss) (net of tax)						
	Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit liability/(asset)	-	-	-	-	-	(20)
	Tax on remeasurement of defined benefit liability/(asset)	-	-	-	-	-	7
	Fair value changes in Equity investments through OCI	180	50	28	256	104	97
	Tax impact of Fair value changes in Equity investments through OCI	(26)	(7)	(3)	(37)	(10)	(8)
	Other comprehensive income/ (loss) for the period/ year, net of tax	154	43	25	219	94	76
9	Total comprehensive income for the period/ year (7+8)	1,403	6,654	1,945	14,442	9,669	13,142
10	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358	358	358
11	Other equity						55,565
12	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)						
	Basic (in ₹)	6.97	36.91	10.72	79.41	53.31	72.79
	Diluted (in ₹)	6.97	36.91	10.72	79.41	53.31	72.79

See accompanying notes to the unaudited standalone financial results.

Continued..



NATCO Pharma Limited

Notes to the unaudited standalone financial results:

- 1) The unaudited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited standalone financial results for the quarter and nine months ended 31-12-2024 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-02-2025.
- 3) The unaudited standalone financial results of the Company for the quarter and nine months ended 31-12-2024, have been reviewed by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the unaudited consolidated financial results.
- 5) The financial results of the following subsidiaries and step-down subsidiaries of the Company are included in the consolidated financial results for the quarter and nine months period ended 31 December 2024:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC (Formerly known as Dash Pharmaceuticals LLC, USA - name changed w.e.f. 12-04-2023)	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited (w.e.f. 04-09-2023)	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma (w.e.f. 28-08-2023)	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S. (w.e.f. 15-08-2023)	Colombia	Wholly owned Subsidiary

- 6) The Board of Directors at their meeting held on 12-02-2025 have approved an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 31-12-2024. An interim dividend of ₹ 3 /- per equity share of ₹ 2 each for the quarter ended 30-06-2024 and an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 30-09-2024 was approved by Board of Directors at their meetings held on 12-08-2024 and 12-11-2024 respectively.

By order of the Board
For NATCO Pharma Limited

V C Nannapaneni
Chairman & Managing Director
(DIN: 00183315)

Place: Hyderabad

Date: 12 February 2025

B S R and Co

Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited standalone financial results of NATCO Pharma Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of NATCO Pharma Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm’s Registration No.:128510W



Amit Kumar Bajaj

Partner

Hyderabad

12 February 2025

Membership No.: 218685

UDIN:25218685BMMKCO7350

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East) Mumbai - 400063

NATCO Pharma Ltd

Natco House

Road No.2, Banjara Hills

Hyderabad-500 034, India

Hyderabad, India, February 12th, 2025: Natco Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for third quarter of financial year 2025.

NATCO records ₹651.1 Crore consolidated revenue and ₹132.4 Crore of profit after tax for Q3 FY25

NATCO recorded consolidated total revenue of ₹651.1 Crore for the third quarter of FY2025 that ended on 31st December 2024, as against ₹795.6 Crore for the same period last year. The net profit for the period, on a consolidated basis, was ₹132.4 Crores as against ₹212.7 Crore same period last year.

During the quarter, contribution from the export formulation business was lower. However, the Company expects healthy growth of business in the ensuing quarters.

The Board of Directors has declared third interim dividend of INR 1.5 per equity share, for FY 2024-25.

Segmental Revenue Split (INR Cr)

Segment	Q3FY25	Q2FY25	Q3FY24
Active Pharmaceutical Ingredients (API)	66.6	49.6	46.3
Domestic Formulations	96.1	102.3	99.4
Formulations export (Incl. profit share and subs)	285.8	1,211.3	605.6
Other operating and non-operating income	187.5	57.6	30.2
Crop Health Sciences (CHS)	15.1	14.1	14.1
Total	651.1	1,434.9	795.6

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in